+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fluindione Market by Formulation, Distribution Channel, Application - Global Forecast to 2030- Product Image
Fluindione Market by Formulation, Distribution Channel, Application - Global Forecast to 2030- Product Image
Sale

Fluindione Market by Formulation, Distribution Channel, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968247
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fluindione Market grew from USD 971.51 million in 2024 to USD 1.02 billion in 2025. It is expected to continue growing at a CAGR of 5.71%, reaching USD 1.35 billion by 2030.

Unveiling the Fluindione Landscape: Executive Overview

The global Fluindione landscape is undergoing profound transformation as stakeholders across the healthcare continuum seek more precise and effective anticoagulant solutions. Once regarded as a niche treatment option in select regions, Fluindione’s unique pharmacological profile has captured renewed interest among clinicians, payers, and patients alike. This executive summary synthesizes key dynamics driving market evolution, highlights pivotal regulatory and economic forces, and outlines strategic imperatives for industry leaders.

As a Vitamin K antagonist agent, Fluindione offers nuanced advantages in specific patient populations while contending with an increasingly crowded portfolio of anticoagulants. To contextualize its future trajectory, this overview examines shifts in clinical practice guidelines, innovation in delivery formats, and the impact of global trade policies on pricing and supply chains. By presenting a high-level orientation to the market’s structure and outlook, decision-makers will be equipped to chart optimized pathways for investment and commercialization.

Pivotal Trends Redefining Fluindione Market Dynamics

Over the past several years, the Fluindione market has been reshaped by a confluence of technological advancements, evolving patient preferences, and heightened regulatory scrutiny. The integration of digital health platforms has empowered clinicians with real-time adherence data, prompting manufacturers to explore connected-device prefilled syringes that enhance dosing accuracy. Concurrently, the proliferation of telemedicine has altered traditional channels of distribution, compelling pharmaceutical companies to devise omnichannel engagement models that bridge hospital settings, community retail pharmacies, and emerging online outlets.

Regulatory agencies have also played a pivotal role, introducing stricter post-authorization safety studies and demanding robust pharmacovigilance frameworks. In response, developers have prioritized formulation refinements that reduce bleeding risks and optimize therapeutic windows. At the same time, economic pressures have galvanized partnerships between established players and biotech innovators to defray development costs and accelerate pipeline diversification. Together, these trends are not only redefining the competitive landscape but also setting new benchmarks for patient-centric care.

Assessing the Ripple Effects of 2025 US Tariff Adjustments

The implementation of tariff revisions in the United States in 2025 has generated significant headwinds for raw material procurement and finished product pricing within the Fluindione supply chain. Increased duties on active pharmaceutical ingredients imported from key manufacturing hubs have compelled producers to reassess procurement strategies and to consider onshore API synthesis partnerships. Consequently, cost increases have reverberated through contract manufacturing organizations, leading some providers to negotiate long-term supply agreements to stabilize input costs.

These shifts have also influenced downstream stakeholders. Hospital and retail pharmacies have faced margin compression as distributors adjust their pricing frameworks to offset tariff-related surcharges. In parallel, manufacturers have weighed the feasibility of passing on incremental costs to payers against the risk of reduced market access. As a result, market participants are increasingly exploring localized production strategies and tiered pricing structures to mitigate the cumulative impact of these trade measures. In this evolving environment, agility in supply chain design and proactive engagement with regulatory bodies will be essential to preserving competitive positioning.

Decoding Segmentation Patterns to Illuminate Market Niches

A nuanced understanding of segmentation reveals the varied trajectories shaping Fluindione adoption across formulation, channel, and clinical application. In the realm of dosage forms, injectable options span both prefilled syringes and solution presentations, catering to acute care settings demanding rapid onset and precise control, while tablet offerings leverage immediate and sustained release technologies to optimize outpatient adherence. Distribution pathways range from hospital pharmacies-serving general and teaching institutions-to digital storefronts that encompass hybrid and pure-play online models, as well as brick-and-mortar retail outlets, both chain and independent.

Clinically, the anticoagulant’s role spans the management of atrial fibrillation through initial and maintenance regimens, acute and long-term strategies for pulmonary embolism, and prophylaxis and treatment protocols targeting venous thrombosis. Each axis of segmentation underscores distinct value propositions and growth potential: enhanced ambulatory care via sustained release tablets, digital engagement through hybrid pharmacy ecosystems, and tailored therapy plans for diverse cardiovascular indications. By aligning product development and marketing initiatives with these nuanced segment insights, stakeholders can unlock incremental market share and foster differentiated positioning.

Regional Nuances Shaping Fluindione Adoption Worldwide

Regional dynamics exert a profound influence on Fluindione’s uptake and strategic emphasis. In the Americas, aging demographics and well-established anticoagulation protocols create a fertile environment for advanced formulations and integrated care models. Across Europe, Middle East and Africa, heterogeneous regulatory frameworks and varying degrees of reimbursement pose both challenges and opportunities, with early-stage markets in Eastern Europe and the GCC demonstrating notable receptivity to innovative delivery systems.

Asia-Pacific markets exhibit rapid growth driven by rising cardiovascular disease prevalence and expanding healthcare infrastructure. Urban centers in East Asia are prioritizing precision medicine, while South and Southeast Asia are investing in regional manufacturing capacity to reduce import dependency. Navigating these regional contours requires tailored market entry strategies, collaboration with local healthcare authorities, and adaptive pricing models that reconcile global best practices with localized economic realities.

Competitive Ecosystem and Strategic Positioning of Leading Players

Leading pharmaceutical entities are harnessing diverse strategies to fortify their positions within the Fluindione space. Strategic alliances and licensing agreements have accelerated access to novel delivery technologies, while targeted acquisitions have broadened global footprint and enriched patent portfolios. Some organizations are scaling up dedicated API production facilities to secure upstream supply, whereas others are directing R&D investments toward combination therapies that integrate Fluindione with complementary agents for enhanced efficacy.

In parallel, companies with robust commercial infrastructures are leveraging advanced analytics to optimize market segmentation and pricing strategies, capitalizing on real-world evidence to substantiate differentiated value propositions with payers. Meanwhile, biotech innovators are carving niches through specialty formulations and focused clinical programs. This competitive mosaic underscores the importance of agility, technological acumen, and strategic collaboration in sustaining long-term growth within the Fluindione arena.

Strategic Imperatives for Sustainable Growth and Innovation

To navigate today’s complex market environment, industry leaders must adopt a multifaceted strategic framework. First, prioritizing formulation innovation-such as exploring novel sustained release mechanisms or integrated digital delivery systems-will strengthen clinical differentiation and patient adherence. Second, expanding channel partnerships with both traditional hospital networks and agile online pharmacy operators will diversify access points and capture shifting consumer preferences.

Engaging with regional regulatory authorities to streamline approval pathways and proactively address tariff-induced cost pressures will safeguard supply continuity and pricing stability. Simultaneously, forging collaborative alliances with diagnostic and digital health providers can unlock value through integrated care offerings. Finally, rigorous post-market surveillance and real-world evidence generation will bolster payer negotiations and reinforce Fluindione’s clinical and economic value narrative.

Rigorous Methodology Ensuring Depth and Reliability

This analysis is grounded in a rigorous research methodology that synthesizes primary and secondary data sources to ensure depth and reliability. Primary research comprised in-depth interviews with key opinion leaders, senior executives from pharmaceutical companies, and procurement specialists across hospital, retail, and online pharmacy sectors. Complementary secondary research drew upon peer-reviewed journals, regulatory filings, patent databases, and proprietary trade statistics.

Data triangulation techniques validated findings through cross-referencing disparate sources, while scenario analysis illuminated potential market trajectories under varying regulatory and economic conditions. Quality control measures, including peer review by external industry experts, assured both analytical rigor and practical relevance. This robust approach underpins the actionable insights presented throughout the report.

Synthesizing Insights to Guide Future Decisions

Throughout this executive summary, Fluindione’s evolving market dynamics have been examined across clinical, commercial, and regulatory dimensions. Emerging delivery technologies, shifting distribution paradigms, and the impact of 2025 US tariff changes collectively shape an environment defined by both opportunity and complexity. Segmentation analysis highlights targeted pathways for growth, while regional insights elucidate tailored strategies to navigate diverse landscapes.

By coupling strategic foresight with evidence-based recommendations, stakeholders are well positioned to enhance competitive resilience, optimize patient outcomes, and drive sustainable market expansion. The synthesis of these insights offers a clear roadmap for informed decision-making, underscoring the critical interplay between innovation, collaboration, and adaptability in the evolving Fluindione ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Formulation
    • Injectable
      • Prefilled Syringe
      • Solution
    • Tablet
      • Immediate Release
      • Sustained Release
  • Distribution Channel
    • Hospital Pharmacy
      • General Hospital
      • Teaching Hospital
    • Online Pharmacy
      • Hybrid
      • Pure-Play
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Application
    • Atrial Fibrillation
      • Initial Therapy
      • Maintenance Therapy
    • Pulmonary Embolism
      • Acute Management
      • Long-Term Management
    • Venous Thrombosis
      • Prophylaxis
      • Treatment
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi S.A.
  • Mylan SAS
  • Teva Santé SAS
  • Sandoz SAS
  • Stada France SAS
  • Biogaran SA
  • Zentiva SA
  • Aurobindo Pharma France SARL
  • Accord Healthcare SAS
  • Ratiopharm SAS

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fluindione Market, by Formulation
8.1. Introduction
8.2. Injectable
8.2.1. Prefilled Syringe
8.2.2. Solution
8.3. Tablet
8.3.1. Immediate Release
8.3.2. Sustained Release
9. Fluindione Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. General Hospital
9.2.2. Teaching Hospital
9.3. Online Pharmacy
9.3.1. Hybrid
9.3.2. Pure-Play
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Fluindione Market, by Application
10.1. Introduction
10.2. Atrial Fibrillation
10.2.1. Initial Therapy
10.2.2. Maintenance Therapy
10.3. Pulmonary Embolism
10.3.1. Acute Management
10.3.2. Long-Term Management
10.4. Venous Thrombosis
10.4.1. Prophylaxis
10.4.2. Treatment
11. Americas Fluindione Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Fluindione Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Fluindione Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Sanofi S.A.
14.3.2. Mylan SAS
14.3.3. Teva Santé SAS
14.3.4. Sandoz SAS
14.3.5. Stada France SAS
14.3.6. Biogaran SA
14.3.7. Zentiva SA
14.3.8. Aurobindo Pharma France SARL
14.3.9. Accord Healthcare SAS
14.3.10. Ratiopharm SAS
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. FLUINDIONE MARKET MULTI-CURRENCY
FIGURE 2. FLUINDIONE MARKET MULTI-LANGUAGE
FIGURE 3. FLUINDIONE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FLUINDIONE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FLUINDIONE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FLUINDIONE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FLUINDIONE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FLUINDIONE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FLUINDIONE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FLUINDIONE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES FLUINDIONE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. FLUINDIONE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. FLUINDIONE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FLUINDIONE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FLUINDIONE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FLUINDIONE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FLUINDIONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FLUINDIONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FLUINDIONE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FLUINDIONE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FLUINDIONE MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FLUINDIONE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FLUINDIONE MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FLUINDIONE MARKET SIZE, BY GENERAL HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FLUINDIONE MARKET SIZE, BY TEACHING HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FLUINDIONE MARKET SIZE, BY HYBRID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FLUINDIONE MARKET SIZE, BY PURE-PLAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FLUINDIONE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FLUINDIONE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FLUINDIONE MARKET SIZE, BY INITIAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FLUINDIONE MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FLUINDIONE MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FLUINDIONE MARKET SIZE, BY LONG-TERM MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FLUINDIONE MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FLUINDIONE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS FLUINDIONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES FLUINDIONE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 67. CANADA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 68. CANADA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. CANADA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 70. CANADA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 71. CANADA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. CANADA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 75. CANADA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. MEXICO FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA FLUINDIONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 134. GERMANY FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 135. GERMANY FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. GERMANY FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 137. GERMANY FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 138. GERMANY FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 139. GERMANY FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. GERMANY FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 142. GERMANY FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 146. FRANCE FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 149. FRANCE FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 153. FRANCE FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 165. ITALY FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 167. ITALY FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 168. ITALY FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. ITALY FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 170. ITALY FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 171. ITALY FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 172. ITALY FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. ITALY FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 175. ITALY FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 177. SPAIN FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 179. SPAIN FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SPAIN FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 181. SPAIN FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 182. SPAIN FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 183. SPAIN FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. SPAIN FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 185. SPAIN FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 186. SPAIN FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. DENMARK FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 222. DENMARK FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 223. DENMARK FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. DENMARK FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 225. DENMARK FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 226. DENMARK FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 227. DENMARK FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. DENMARK FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 230. DENMARK FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 242. QATAR FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. QATAR FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 244. QATAR FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 245. QATAR FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. QATAR FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 247. QATAR FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 248. QATAR FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 249. QATAR FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. QATAR FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 252. QATAR FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 253. FINLAND FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 254. FINLAND FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 255. FINLAND FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 256. FINLAND FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. FINLAND FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. FINLAND FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 259. FINLAND FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 260. FINLAND FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. FINLAND FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 262. FINLAND FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 263. FINLAND FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 286. EGYPT FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 287. EGYPT FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 288. EGYPT FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 289. EGYPT FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. EGYPT FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 291. EGYPT FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 292. EGYPT FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 293. EGYPT FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. EGYPT FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 296. EGYPT FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 297. TURKEY FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 298. TURKEY FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 299. TURKEY FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 300. TURKEY FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. TURKEY FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 302. TURKEY FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 303. TURKEY FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 304. TURKEY FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. TURKEY FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 306. TURKEY FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 307. TURKEY FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 319. NORWAY FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. NORWAY FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 321. NORWAY FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 322. NORWAY FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. NORWAY FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 324. NORWAY FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 325. NORWAY FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 326. NORWAY FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 327. NORWAY FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 328. NORWAY FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 329. NORWAY FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 330. POLAND FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. POLAND FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 332. POLAND FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 333. POLAND FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. POLAND FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 335. POLAND FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 336. POLAND FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 337. POLAND FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. POLAND FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 339. POLAND FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 340. POLAND FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 348. SWITZERLAND FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 349. SWITZERLAND FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 350. SWITZERLAND FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 351. SWITZERLAND FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 352. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 353. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 354. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 355. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 356. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 357. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 358. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 359. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 360. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
TABLE 361. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2030 (USD MILLION)
TABLE 362. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY VENOUS THROMBOSIS, 2018-2030 (USD MILLION)
TABLE 363. ASIA-PACIFIC FLUINDIONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 364. CHINA FLUINDIONE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 365. CHINA FLUINDIONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 366. CHINA FLUINDIONE MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 367. CHINA FLUINDIONE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 368. CHINA FLUINDIONE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 369. CHINA FLUINDIONE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 370. CHINA FLUINDIONE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 371. CHINA FLUINDIONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 372. CHINA FLUINDIONE MARKET SIZE, BY ATRIAL FIBRILLATION, 2018-2030 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Fluindione market report include:
  • Sanofi S.A.
  • Mylan SAS
  • Teva Santé SAS
  • Sandoz SAS
  • Stada France SAS
  • Biogaran SA
  • Zentiva SA
  • Aurobindo Pharma France SARL
  • Accord Healthcare SAS
  • Ratiopharm SAS

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.35 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Fluindione (CAS 957-56-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Fluindione (CAS 957-56-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030 - Product Image

Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Anisindione Market by Product Type, Application, Distribution Channel - Global Forecast to 2030 - Product Image

Anisindione Market by Product Type, Application, Distribution Channel - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Antithrombotic Drugs - Global Strategic Business Report - Product Image

Antithrombotic Drugs - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From

About the Fluindione Market

Fluindione is a hematological drug used to treat and prevent thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It is a vitamin K antagonist, meaning it works by blocking the action of vitamin K in the body, which is necessary for the formation of blood clots. Fluindione is available in both oral and injectable forms, and is often used in combination with other anticoagulants. It is also used to treat atrial fibrillation, a type of irregular heartbeat. The Fluindione market is highly competitive, with a number of major pharmaceutical companies offering their own versions of the drug. These include Bayer, Pfizer, Sanofi, and Bristol-Myers Squibb. Generic versions of the drug are also available, produced by a variety of generic drug manufacturers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.